Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
in 20 patients, chronic GVHD in 10 patients, and acute myeloid leukemia in 1 patient. Group 2 had better outcomes compared with group 1, with an overall survival rate of 100% versus 88% and an event-free ...
reported and eventually recruited 10 patients [52]. A combination of a relatively high cell dose and transduction efficiency led to gene marking across both myeloid and lymphoid lineages. A marked clinical ...
to integrate at enhancers in lymphoid tumors independently of the distance to the TSS (Sokol et al., 2014) and the rate and type of tumour formation is controlled by enhancer activity within the U3 region ...
lapatinib for the treatment of HER2-amplified breast cancers,3 the Abl kinase SMI imatinib, which blocks the activity of a Bcr-Abl fusion protein in chronic myeloid leukemia (CML),4 the SMI gefitinib, which ...
in a gene therapy trial for chronic granulomatous disease, where the expansion of gene-modified cells in two patients was associated with insertions into, or near one or more of, the MDS1-EVI1, PRDM16 ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!